<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Health Forum</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Health Forum</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Health Forum</journal-title></journal-title-group><issn pub-type="epub">2689-0186</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10220518</article-id><article-id pub-id-type="pmcid-ver">PMC10220518.1</article-id><article-id pub-id-type="pmcaid">10220518</article-id><article-id pub-id-type="pmcaiid">10220518</article-id><article-id pub-id-type="pmid">37234015</article-id><article-id pub-id-type="doi">10.1001/jamahealthforum.2023.1102</article-id><article-id pub-id-type="publisher-id">aoi230025</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="domain" specific-use="print"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-only"><subject>Online Only</subject></subj-group><subj-group subj-group-type="allowCommenting"><subject>Comments</subject></subj-group></article-categories><title-group><article-title>Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment</article-title><alt-title alt-title-type="headline">Association of State Policies With Per Capita Buprenorphine Treatment</alt-title><alt-title alt-title-type="running-head">Association of State Policies With Per Capita Buprenorphine Treatment</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Stein</surname><given-names initials="BD">Bradley D.</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref rid="aoi230025aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saloner</surname><given-names initials="BK">Brendan K.</given-names></name><degrees>PhD</degrees><xref rid="aoi230025aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Golan</surname><given-names initials="OK">Olivia K.</given-names></name><degrees>MHA</degrees><xref rid="aoi230025aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Andraka-Christou</surname><given-names initials="B">Barbara</given-names></name><degrees>JD</degrees><degrees>PhD</degrees><xref rid="aoi230025aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Andrews</surname><given-names initials="CM">Christina M.</given-names></name><degrees>PhD</degrees><xref rid="aoi230025aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dick</surname><given-names initials="AW">Andrew W.</given-names></name><degrees>PhD</degrees><xref rid="aoi230025aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Davis</surname><given-names initials="CS">Corey S.</given-names></name><degrees>JD</degrees><degrees>MSPH</degrees><xref rid="aoi230025aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sheng</surname><given-names initials="F">Flora</given-names></name><degrees>MBBS</degrees><degrees>MPH</degrees><xref rid="aoi230025aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gordon</surname><given-names initials="AJ">Adam J.</given-names></name><degrees>MD</degrees><degrees>MPH</degrees><xref rid="aoi230025aff9" ref-type="aff">
<sup>9</sup>
</xref><xref rid="aoi230025aff10" ref-type="aff">
<sup>10</sup>
</xref></contrib></contrib-group><aff id="aoi230025aff1"><label>1</label>RAND Corporation, Pittsburgh, Pennsylvania</aff><aff id="aoi230025aff2"><label>2</label>Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland</aff><aff id="aoi230025aff3"><label>3</label>School of Public Health, Georgia State University, Atlanta</aff><aff id="aoi230025aff4"><label>4</label>School of Global Health Management and Informatics, University of Central Florida, Orlando</aff><aff id="aoi230025aff5"><label>5</label>Arnold School of Public Health, University of South Carolina, Columbia</aff><aff id="aoi230025aff6"><label>6</label>RAND Corporation, Boston, Massachusetts</aff><aff id="aoi230025aff7"><label>7</label>Network for Public Health Law, Los Angeles, California</aff><aff id="aoi230025aff8"><label>8</label>RAND Corporation, Arlington, Virginia</aff><aff id="aoi230025aff9"><label>9</label>Program for Addiction Research, Clinical Care, Knowledge and Advocacy, Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City</aff><aff id="aoi230025aff10"><label>10</label>Informatics, Decision-Enhancement, and Analytic Sciences Center, VA Salt Lake City Health Care System, Salt Lake City, Utah</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> March 24, 2023.</p><p content-type="published-online"><bold>Published:</bold> May 26, 2023. doi:<uri content-type="doi">10.1001/jamahealthforum.2023.1102</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. &#169; 2023 Stein BD et al. <italic toggle="yes">JAMA Health Forum</italic>.</p><corresp id="aoi230025cor1"><bold>Corresponding Author:</bold> Bradley D. Stein, MD, PhD, RAND Corporation, 4570 Fifth Ave, Ste 600, Pittsburgh, PA 15213 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="stein@rand.org">stein@rand.org</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Stein had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic toggle="yes">Concept and design</italic>: Stein, Dick, Gordon.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data</italic>: Stein, Saloner, Golan, Andraka-Christou, Andrews, Davis, Sheng, Gordon.</p><p><italic toggle="yes">Drafting of the manuscript</italic>: Stein, Dick, Sheng.</p><p><italic toggle="yes">Critical revision of the manuscript for important intellectual content</italic>: Saloner, Golan, Andraka-Christou, Andrews, Davis, Sheng, Gordon.</p><p><italic toggle="yes">Statistical analysis</italic>: Dick, Sheng.</p><p><italic toggle="yes">Obtained funding</italic>: Stein, Dick.</p><p><italic toggle="yes">Administrative, technical, or material support</italic>: Andrews, Davis, Sheng.</p><p><italic toggle="yes">Supervision</italic>: Gordon.</p><p><italic toggle="yes">Legal data collection and analysis</italic>: Andraka-Christou.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Stein reported receiving grants from the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), during the conduct of the study and grants from the FORE Foundation and National Institute of Mental Health outside the submitted work. Dr Andraka-Christou reported receiving grants from the NIDA/NIH; Maternal and Child Health Bureau, Health Resources and Services Administration; the Health Foundation of South Florida; and the Justice Community Innovation Network and personal fees from Arizona State University, the University of Arizona, Emory University, Wayne State University, and Florida State University outside the submitted work. Dr Andrews reported receiving grants from the NIDA and National Institute on Alcohol Abuse and Alcoholism outside the submitted work. Dr Gordon reported receiving grants to his university from the Department of Veterans Affairs, NIH, and US Department of Health and Human Services and personal fees from UpToDate outside the submitted work. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> This study was supported by grants P50DA046351 (Dr Stein), R01DA048500 (Dr Stein), and K01DA042139 (Dr Saloner) from the National Institute on Drug Abuse.</p><p><bold>Role of the Funder/Sponsor:</bold> The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-AOI230025-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p><p><bold>Additional Contributions:</bold> The authors thank Hilary Peterson, BA, and Mary Vaiana, PhD, of the RAND Corporation for their feedback and editorial assistance on earlier versions of the manuscript. Neither received additional compensation beyond their RAND salary. The authors also thank Derek Carr, JD, Network for Public Health Law, for assistance with legal data acquisition. He was not compensated for his contribution.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2023-05-26T10:00"><day>26</day><month>5</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2023</year></pub-date><volume>4</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">436793</issue-id><elocation-id>e231102</elocation-id><history><date date-type="received"><day>29</day><month>8</month><year>2022</year></date><date date-type="accepted"><day>24</day><month>3</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>05</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>28</day><month>05</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-18 08:25:14.893"><day>18</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright 2023 Stein BD et al. <italic toggle="yes">JAMA Health Forum</italic>.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamahealthforum-e231102.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamahealthforum-e231102.pdf">jamahealthforum-e231102.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/channels/health-forum/fullarticle/10.1001/jamahealthforum.2023.1102"/><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-aoi230025-1"><title>Question</title><p>What is the association between selected state policies and buprenorphine dispensing?</p></sec><sec id="ab-aoi230025-2"><title>Findings</title><p>In this cross-sectional study using US county-level pharmacy claims data, educational requirements for buprenorphine prescribers beyond those required to obtain a waiver were associated with increased buprenorphine dispensing, as was continuing medical education related to substance misuse and addiction. Prescription drug monitoring programs, pain management clinic laws, and Medicaid policies had no association with buprenorphine dispensing.</p></sec><sec id="ab-aoi230025-3"><title>Meaning</title><p>These findings suggest that meaningful changes in access to buprenorphine may be achieved through greater attention to professional education and clinician knowledge.</p></sec></abstract><abstract abstract-type="teaser" specific-use="electronic"><p>This cross-sectional study uses US county-level pharmacy claims data to examine the association of selected state policies with rates of buprenorphine treatment.</p></abstract><abstract><sec id="ab-aoi230025-4"><title>Importance</title><p>Expanding the use of buprenorphine for treating opioid use disorder is a critical component of the US response to the opioid crisis, but few studies have examined how state policies are associated with buprenorphine dispensing.</p></sec><sec id="ab-aoi230025-5"><title>Objective</title><p>To examine the association of 6 selected state policies with the rate of individuals receiving buprenorphine per 1000 county residents.</p></sec><sec id="ab-aoi230025-6"><title>Design, Setting, and Participants</title><p>This cross-sectional study used 2006 to 2018 US retail pharmacy claims data for individuals dispensed buprenorphine formulations indicated for treating opioid use disorder.</p></sec><sec id="ab-aoi230025-7"><title>Exposures</title><p>State implementation of policies requiring additional education for buprenorphine prescribers beyond waiver training, continuing medical education related to substance misuse and addiction, Medicaid coverage of buprenorphine, Medicaid expansion, mandatory prescriber use of prescription drug monitoring programs, and pain management clinic laws were examined.</p></sec><sec id="ab-aoi230025-8"><title>Main Outcomes and Measures</title><p>The main outcome was buprenorphine treatment months per 1000 county residents as measured using multivariable longitudinal models. Statistical analyses were conducted from September 1, 2021, through April 30, 2022, with revised analyses conducted through February 28, 2023.</p></sec><sec id="ab-aoi230025-9"><title>Results</title><p>The mean (SD) number of months of buprenorphine treatment per 1000 persons nationally increased steadily from 1.47 (0.04) in 2006 to 22.80 (0.55) in 2018. Requiring that buprenorphine prescribers receive additional education beyond that required to obtain the federal X-waiver was associated with significant increases in the number of months of buprenorphine treatment per 1000 population in the 5 years following implementation of the requirement (from 8.51 [95% CI, 2.36-14.64] months in year 1 to 14.43 [95% CI, 2.61-26.26] months in year 5). Requiring continuing medical education for physician licensure related to substance misuse or addiction was associated with significant increases in buprenorphine treatment per 1000 population in each of the 5 years following policy implementation (from 7.01 [95% CI, 3.17-10.86] months in the first year to 11.43 [95% CI, 0.61-22.25] months in the fifth year). None of the other policies examined was associated with a significant change in buprenorphine months of treatment per 1000 county residents.</p></sec><sec id="ab-aoi230025-10"><title>Conclusions and Relevance</title><p>In this cross-sectional study of US pharmacy claims, state-mandated educational requirements beyond the initial training required to prescribe buprenorphine were associated with increased buprenorphine use over time. The findings suggest requiring education for buprenorphine prescribers and training in substance use disorder treatment for all controlled substance prescribers as an actionable proposal for increasing buprenorphine use, ultimately serving more patients. No single policy lever can ensure adequate buprenorphine supply; however, policy maker attention to the benefits of enhancing clinician education and knowledge may help to expand buprenorphine access.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="H1-1-AOI230025"><title>Introduction</title><p>The number of fatal opioid overdoses in the US continues to soar,<sup><xref rid="aoi230025r1" ref-type="bibr">1</xref></sup> and an estimated 1.6 million individuals in the country have an opioid use disorder (OUD).<sup><xref rid="aoi230025r2" ref-type="bibr">2</xref>,<xref rid="aoi230025r3" ref-type="bibr">3</xref></sup> Medication treatment for opioid use disorder (MOUD)<sup><xref rid="aoi230025r4" ref-type="bibr">4</xref></sup> is considered the standard of care,<sup><xref rid="aoi230025r5" ref-type="bibr">5</xref></sup> improving quality of life and decreasing fatal overdose rates.<sup><xref rid="aoi230025r6" ref-type="bibr">6</xref>,<xref rid="aoi230025r7" ref-type="bibr">7</xref>,<xref rid="aoi230025r8" ref-type="bibr">8</xref>,<xref rid="aoi230025r9" ref-type="bibr">9</xref></sup> Provision of MOUD in the US has grown substantially over the past 2 decades,<sup><xref rid="aoi230025r10" ref-type="bibr">10</xref>,<xref rid="aoi230025r11" ref-type="bibr">11</xref></sup> driven largely by expansion in buprenorphine use.<sup><xref rid="aoi230025r12" ref-type="bibr">12</xref>,<xref rid="aoi230025r13" ref-type="bibr">13</xref></sup> Despite this growth, less than one-third of individuals with OUD receive MOUD.<sup><xref rid="aoi230025r4" ref-type="bibr">4</xref>,<xref rid="aoi230025r14" ref-type="bibr">14</xref></sup></p><p>Historically, federal law restricted buprenorphine prescribing for OUD to clinicians who obtained special permission from the federal government (commonly referred to as an X-waiver).<sup><xref rid="aoi230025r15" ref-type="bibr">15</xref>,<xref rid="aoi230025r16" ref-type="bibr">16</xref></sup> Before the waiver requirement was removed at the end of 2022, most medical practitioners were required to receive 8 hours (physicians) or 24 hours (advanced practice clinicians) of specialized education to obtain one. Prior to the removal of the waiver requirement, the federal government and some state governments had enacted other policies that might influence the buprenorphine prescribing workforce, including increasing the number of patients waivered clinicians were permitted to treat,<sup><xref rid="aoi230025r17" ref-type="bibr">17</xref></sup> allowing advanced practice clinicians to prescribe buprenorphine for OUD,<sup><xref rid="aoi230025r17" ref-type="bibr">17</xref>,<xref rid="aoi230025r18" ref-type="bibr">18</xref></sup> implementing mentoring and external facilitation intervention programs,<sup><xref rid="aoi230025r19" ref-type="bibr">19</xref>,<xref rid="aoi230025r20" ref-type="bibr">20</xref>,<xref rid="aoi230025r21" ref-type="bibr">21</xref></sup> requiring additional continuing medical education (CME) for buprenorphine prescribers,<sup><xref rid="aoi230025r22" ref-type="bibr">22</xref></sup> and requiring training in substance use disorder treatment for all controlled substance prescribers.<sup><xref rid="aoi230025r23" ref-type="bibr">23</xref></sup></p><p>The number of buprenorphine prescribers has grown substantially. However, many clinicians stop prescribing buprenorphine within 1 year of their first dispensed prescription,<sup><xref rid="aoi230025r24" ref-type="bibr">24</xref></sup> and most active prescribers treat few individuals.<sup><xref rid="aoi230025r25" ref-type="bibr">25</xref>,<xref rid="aoi230025r26" ref-type="bibr">26</xref>,<xref rid="aoi230025r27" ref-type="bibr">27</xref>,<xref rid="aoi230025r28" ref-type="bibr">28</xref></sup> As a result, growth in the number of buprenorphine prescribers has not translated to comparable increases in buprenorphine use.</p><p>Multiple studies have examined how state policies affect buprenorphine access directly or affect proximal outcomes, such as the number of waivered clinicians. These studies have examined policies that affect the buprenorphine prescribing workforce directly as well as policies that could influence buprenorphine use through other mechanisms, such as financing, general clinician education, increasing demand for treatment, or Medicaid expansion.<sup><xref rid="aoi230025r29" ref-type="bibr">29</xref>,<xref rid="aoi230025r30" ref-type="bibr">30</xref>,<xref rid="aoi230025r31" ref-type="bibr">31</xref></sup> Other studies have examined policies requiring prescribers to use prescription drug monitoring programs (hereafter, mandatory PDMPs) and regulating pain management clinics.<sup><xref rid="aoi230025r32" ref-type="bibr">32</xref></sup> However, cross-study comparisons are challenging due to differences in measurement and sample selection. In addition, studies have often assessed effects of a single policy, although states often implement multiple policies that could influence buprenorphine access. To our knowledge, there are no national studies of the general population examining how state policies affect receipt of buprenorphine treatment, exploring how policy outcomes evolve over time, or disentangling how multiple policies implemented within a state could influence buprenorphine dispensing.<sup><xref rid="aoi230025r33" ref-type="bibr">33</xref></sup></p><p>To better understand how selected state policies are associated with buprenorphine dispensing, we examined the association of state policies with the rate of buprenorphine dispensing per 1000 county residents. Understanding such associations and the speed at which changes in buprenorphine use occur can inform policy maker efforts to enhance availability of buprenorphine treatment.</p></sec><sec id="H1-2-AOI230025"><title>Methods</title><sec id="H2-1-AOI230025"><title>Data and Measures</title><p>In this cross-sectional study, we used deidentified pharmacy claims data from the IQVIA Real World Data&#8211;Longitudinal Prescriptions data set,<sup><xref rid="aoi230025r34" ref-type="bibr">34</xref></sup> which captures approximately 90% of prescriptions filled at retail pharmacies in all 50 states and the District of Columbia. We identified prescriptions for buprenorphine formulations with a US Food and Drug Administration&#8211;approved indication for OUD treatment dispensed from January 1, 2006, through December 31, 2018. Analyses were conducted from September 1, 2021, through April 30, 2022, with revised analyses conducted through February 28, 2023. The study adheres to the Strengthening the Reporting of Observational Studies in Epidemiology (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.equator-network.org/reporting-guidelines/strobe/" ext-link-type="uri">STROBE</ext-link>) reporting guidelines for cross-sectional studies and was approved by the RAND institutional review board with a waiver of consent because the research used secondary data sets that did not contain information to identify or contact individuals.</p><p>We first defined buprenorphine treatment episodes. Episodes began with the first observed buprenorphine prescription dispensed with no buprenorphine prescription dispensed in the prior 90 days; the episode ended when the days&#8217; supply from prior prescriptions was exhausted and there were no subsequent buprenorphine prescriptions within 30 days. If an individual was in an episode in any part of a calendar month, we considered that month an active treatment month for the individual. The prescriber responsible for most days&#8217; supply in the episode was designated as the primary prescriber; we used the 5-digit Federal Information Process Standard code of the episode&#8217;s primary prescriber to determine the county in which the episode occurred. We aggregated active buprenorphine episodes for each calendar month at the county level to generate per capita rates of active treatment months for each county using data from the US Census Bureau.<sup><xref rid="aoi230025r35" ref-type="bibr">35</xref></sup> We smoothed the data with linear extrapolation and controlled for county-level factors previously found to be associated with buprenorphine dispensing or the number of waivered buprenorphine clinicians.</p></sec><sec id="H2-2-AOI230025"><title>County Measures</title><p>Based on Rural-Urban Continuum Codes (RUCC) from the Area Health Resources Files, we classified counties as metropolitan (RUCC 1, 2, or 3) or rural (RUCC 4-9).<sup><xref rid="aoi230025r36" ref-type="bibr">36</xref></sup> We calculated county drug overdose rates as the per capita rate of overdose deaths using the restricted multiple cause of death mortality file from the Centers for Disease Control and Prevention<sup><xref rid="aoi230025r37" ref-type="bibr">37</xref></sup> and, given prior studies documenting differences in buprenorphine distribution by percentage of non-White county residents,<sup><xref rid="aoi230025r38" ref-type="bibr">38</xref></sup> from the American Community Survey.<sup><xref rid="aoi230025r39" ref-type="bibr">39</xref></sup></p></sec><sec id="H2-3-AOI230025"><title>Policy Measures</title><p>Our analysis included 6 state-level policies (<xref rid="aoi230025t1" ref-type="table">Table 1</xref>). Our choice of policies was a function of those that have been found in the literature to be associated with buprenorphine prescribing or waivered prescribers (Medicaid coverage, Medicaid expansion, mandatory PDMPs, pain management clinic regulations); policies that conceptually could influence knowledge and behaviors related to substance use disorder and OUD treatment, even if not previously examined empirically; and our ability to obtain policy information for all or almost all states over the study period.</p><table-wrap position="float" id="aoi230025t1" orientation="portrait"><label>Table 1. </label><caption><title>Description of Selected State Policies</title></caption><table frame="hsides" rules="groups"><col width="29.78%" span="1"/><col width="70.22%" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">State policy</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Description</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Mandatory PDMP</td><td valign="top" align="left" rowspan="1" colspan="1">A state has an operational PDMP and mandates that prescribers in that state check the PDMP before prescribing opioids for a patient. States that only mandate use by pharmacists or dispensers are not included in this definition.<sup><xref rid="aoi230025r40" ref-type="bibr">40</xref></sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pain management clinic laws</td><td valign="top" align="left" rowspan="1" colspan="1">Laws that identify specific clinics focused on pain management, regulate personnel and oversight, and regulate the prescribing practices of clinicians working in those clinics.<sup><xref rid="aoi230025r41" ref-type="bibr">41</xref></sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Additional education for buprenorphine prescribers</td><td valign="top" align="left" rowspan="1" colspan="1">Policies requiring additional education for buprenorphine prescribers in addition to the education required to obtain an X-waiver.<sup><xref rid="aoi230025r22" ref-type="bibr">22</xref></sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CME related to substance misuse and addiction for licensure</td><td valign="top" align="left" rowspan="1" colspan="1">Policies requiring CME related to substance misuse and addiction for licensure.</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Medicaid coverage of buprenorphine</td><td valign="top" align="left" rowspan="1" colspan="1">The state Medicaid agency covers buprenorphine for the treatment of opioid use disorder.<sup><xref rid="aoi230025r42" ref-type="bibr">42</xref></sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Medicaid expansion</td><td valign="top" align="left" rowspan="1" colspan="1">The state expanded Medicaid coverage under the Affordable Care Act.<sup><xref rid="aoi230025r43" ref-type="bibr">43</xref></sup></td></tr></tbody></table><table-wrap-foot><p>Abbreviations: CME, continuing medical education; PDMP, prescription drug monitoring program.</p></table-wrap-foot></table-wrap><p>We identified the month in which a state implemented mandatory PDMPs from the OPTIC-Vetted Policy Data Set,<sup><xref rid="aoi230025r40" ref-type="bibr">40</xref></sup> which reviews laws and documents decisions made in creating data sets. We obtained information on the month a state implemented a pain management clinic law from the Prescription Drug Abuse Policy System, which conducts a legal review.<sup><xref rid="aoi230025r41" ref-type="bibr">41</xref></sup> We searched the Westlaw legal database to identify the month in which a state required additional education for buprenorphine prescribers beyond the X-waiver requirement or required CME related to substance misuse and addiction for licensure.<sup><xref rid="aoi230025r22" ref-type="bibr">22</xref>,<xref rid="aoi230025r44" ref-type="bibr">44</xref></sup> Information on Medicaid coverage of buprenorphine was derived from surveys of state Medicaid officials, including 1 in 2013 to 2014<sup><xref rid="aoi230025r42" ref-type="bibr">42</xref></sup> and another in 2020 (unpublished data). We obtained information regarding state Medicaid expansion under the Affordable Care Act from the Kaiser Family Foundation.<sup><xref rid="aoi230025r43" ref-type="bibr">43</xref></sup> Medicaid covers approximately 40% of all OUD treatment.<sup><xref rid="aoi230025r45" ref-type="bibr">45</xref></sup> Changes in Medicaid policy have been associated with changes in the use of buprenorphine among Medicaid enrollees and in other patient populations.<sup><xref rid="aoi230025r46" ref-type="bibr">46</xref></sup> The <xref rid="aoi230025f1" ref-type="fig">Figure</xref> shows the year in which states implemented each policy.</p><fig position="float" id="aoi230025f1" fig-type="figure" orientation="portrait"><label>Figure. </label><caption><title>Month and Year of Implementation of Selected State Policies, January 2006 to December 2018</title><p>ACA indicates the Affordable Care Act; CME, continuing medical education; PDMP, prescription drug monitoring program.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jamahealthforum-e231102-g001.jpg"/></fig></sec><sec id="H2-4-AOI230025"><title>Statistical Analysis</title><p>To examine the association of selected state policies with county-level per capita rates of active buprenorphine treatment, we specified a multivariable event-time model to assess multiple policies simultaneously, adapting work by Borusyak et al<sup><xref rid="aoi230025r47" ref-type="bibr">47</xref></sup> and Goodman-Bacon.<sup><xref rid="aoi230025r48" ref-type="bibr">48</xref></sup> Our model controls for county characteristics and for other state policies that may be associated with rates of buprenorphine treatment. States implemented different policies at different times. Therefore, for each county-month, we defined event-time indicators as the months since (or until) each policy was implemented (the event), with the exception of Medicaid coverage of buprenorphine, for which we only had information on the first year each state had coverage. Therefore we used the midpoint (July 1) of the first year the state had Medicaid coverage as the date on which the policy was implemented. We included event-time indicators for months before policy adoption to identify endogenous policy adoption (ie, policies adopted in response to worsening conditions, such as increased need for treatment) or anticipatory effects (eg, policy effects on outcomes before policy implementation, possibly as a result of preparing for the policy).</p><p>To distinguish policy effects from secular trends, we included calendar-time indicators as main effects. To allow for states that adopted different policies to have different secular trends, we included calendar-time interactions with groups of states that ever adopted each policy.</p><p>Using county-month as the unit of observation, we specified ordinary least squares models of per capita rates of active buprenorphine treatment episodes as a function of policy event-time indicators, calendar-time indicators, calendar-time indicators interaction with state policy groups, and county characteristics. We also included state fixed effects and calculated Huber-White robust SEs clustered at the state level. Finally, we applied weights that were proportional to county population and summed to 1 in each state-month. Thus, observations were representative of states, and the models generated state average policy associations.</p><p>In the eMethods in <xref rid="note-AOI230025-1-s" ref-type="supplementary-material">Supplement 1</xref>, we detail how we determined the best specification for prepolicy implementation association. We first examined the full set of event-time indicators before the policy was implemented. Finding no significant associations before 1 year, we focused on the 12 months before policy implementation. We found evidence of positive associations during that period with 2 of the policies (requirements for additional education of buprenorphine prescribers and CME); we used the period 13 months before implementation as the referent to address anticipatory effects. For the remaining 4 policies, we restricted the event-time indicators for the last month before policy implementation to 0. We present the estimates and 95% CIs of the change in total treatment months per capita for each 1-year period postpolicy adoption from the first to the fifth year. The statistical analysis was performed using SAS, version 9.4 software (SAS Institute Inc).</p></sec></sec><sec id="H1-3-AOI230025"><title>Results</title><p>The mean (SD) number of months of buprenorphine treatment per 1000 persons nationally increased steadily from 1.47 (0.04) in 2006 to 22.80 (0.55) in 2018 (<xref rid="aoi230025t2" ref-type="table">Table 2</xref>). Controlling for county characteristics and other policies, we found that required education of buprenorphine prescribers beyond the waiver requirement was associated with significant increases in the number of months of buprenorphine treatment per capita in the year following policy implementation (an increase of 8.51 treatment months per 1000 population in the first year; 95% CI, 2.36-14.64 months). The magnitude of the association increased in each of the 5 years following implementation to 14.43 months of treatment per 1000 population in the fifth year (95% CI, 2.61-26.26) (<xref rid="aoi230025t3" ref-type="table">Table 3</xref>). Requiring CME for physician licensure related to substance misuse and addiction was also associated with a significant increase in buprenorphine use in each of the 5 years following implementation (an increase of 7.01 treatment months per 1000 population in the first year; 95% CI, 3.17-10.86 months), growing to 11.43 treatment months per 1000 population in the fifth year (95% CI, 0.61-22.25 months). In contrast, after controlling for county characteristics and other policies implemented, we found no association between buprenorphine months of treatment per 1000 county residents and Medicaid expansion, Medicaid coverage of buprenorphine, pain management clinic regulations, or mandatory PDMPs.</p><table-wrap position="float" id="aoi230025t2" orientation="portrait"><label>Table 2. </label><caption><title>Buprenorphine Months of Treatment per 1000 Persons in the US, per Year, 2006-2018</title></caption><table frame="hsides" rules="groups"><col width="55.22%" span="1"/><col width="44.78%" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Variable</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Mean (SD) months</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Year</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2006</td><td valign="top" align="left" rowspan="1" colspan="1">1.47 (0.04)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2007</td><td valign="top" align="left" rowspan="1" colspan="1">2.85 (0.07)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2008</td><td valign="top" align="left" rowspan="1" colspan="1">4.71 (0.10)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2009</td><td valign="top" align="left" rowspan="1" colspan="1">6.38 (0.13)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2010</td><td valign="top" align="left" rowspan="1" colspan="1">7.43 (0.15)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2011</td><td valign="top" align="left" rowspan="1" colspan="1">8.92 (0.18)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2012</td><td valign="top" align="left" rowspan="1" colspan="1">10.86 (0.22)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2013</td><td valign="top" align="left" rowspan="1" colspan="1">12.82 (0.26)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2014</td><td valign="top" align="left" rowspan="1" colspan="1">14.47 (0.32)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2015</td><td valign="top" align="left" rowspan="1" colspan="1">16.09 (0.37)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2016</td><td valign="top" align="left" rowspan="1" colspan="1">17.55 (0.41)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2017</td><td valign="top" align="left" rowspan="1" colspan="1">19.95 (0.48)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2018</td><td valign="top" align="left" rowspan="1" colspan="1">22.80 (0.55)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">County urbanicity</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Urban</td><td valign="top" align="left" rowspan="1" colspan="1">11.68 (0.45)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Rural</td><td valign="top" align="left" rowspan="1" colspan="1">8.70 (0.20)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">County fatal overdose rate, quartile</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1 (Lowest)</td><td valign="top" align="left" rowspan="1" colspan="1">3.25 (0.09)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2</td><td valign="top" align="left" rowspan="1" colspan="1">6.84 (0.21)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 3</td><td valign="top" align="left" rowspan="1" colspan="1">10.56 (0.33)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 4 (Highest)</td><td valign="top" align="left" rowspan="1" colspan="1">19.80 (0.46)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">County percentage of non-White residents, quartile<xref rid="aoi230025t2n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1 (Lowest)</td><td valign="top" align="left" rowspan="1" colspan="1">14.01 (0.29)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2</td><td valign="top" align="left" rowspan="1" colspan="1">13.23 (0.37)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 3</td><td valign="top" align="left" rowspan="1" colspan="1">13.05 (0.31)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 4 (Highest)</td><td valign="top" align="left" rowspan="1" colspan="1">9.33 (0.29)</td></tr></tbody></table><table-wrap-foot><fn id="aoi230025t2n1"><label>
<sup>a</sup>
</label><p>Calculated based on race and ethnicity categories from the American Community Survey.<sup><xref rid="aoi230025r39" ref-type="bibr">39</xref></sup></p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="aoi230025t3" orientation="portrait"><label>Table 3. </label><caption><title>Annual Change in Buprenorphine Treatment Months per 1000 County Residents in 5 Years Following Policy Implementation<xref rid="aoi230025t3n1" ref-type="table-fn"><sup>a</sup></xref></title></caption><table frame="hsides" rules="groups"><col width="9.72%" span="1"/><col width="14.98%" span="1"/><col width="14.57%" span="1"/><col width="15.17%" span="1"/><col width="15.17%" span="1"/><col width="15.22%" span="1"/><col width="15.17%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Year since policy adoption</th><th colspan="6" valign="top" align="left" scope="colgroup" rowspan="1">Effect (95% CI)</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Required additional education for buprenorphine prescribers</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Required CME related to substance misuse and addiction</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Medicaid coverage of buprenorphine</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Medicaid expansion</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Mandatory PDMP</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Pain management clinic regulations</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">First</td><td valign="top" align="left" rowspan="1" colspan="1">8.51 (2.36 to 14.64)</td><td valign="top" align="left" rowspan="1" colspan="1">7.01 (3.17 to 10.86)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;1.73 (&#8722;4.33 to 0.88)</td><td valign="top" align="left" rowspan="1" colspan="1">0.09 (&#8722;6.22 to 6.40)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;2.62 (&#8722;8.10 to 2.85)</td><td valign="top" align="left" rowspan="1" colspan="1">2.20 (&#8722;2.17 to 6.57)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Second</td><td valign="top" align="left" rowspan="1" colspan="1">12.54 (4.63 to 20.44)</td><td valign="top" align="left" rowspan="1" colspan="1">9.97 (3.46 to 16.48)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;1.82 (&#8722;4.78 to 1.14)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.72 (&#8722;9.37 to 7.93)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;2.10 (&#8722;10.92 to 6.73)</td><td valign="top" align="left" rowspan="1" colspan="1">2.59 (&#8722;3.08 to 8.26)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Third</td><td valign="top" align="left" rowspan="1" colspan="1">12.85 (2.05 to 23.66)</td><td valign="top" align="left" rowspan="1" colspan="1">8.95 (1.95 to 15.95)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;1.78 (&#8722;5.06 to 1.50)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.80 (&#8722;11.85 to 10.25)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;2.42 (&#8722;15.57 to 10.72)</td><td valign="top" align="left" rowspan="1" colspan="1">3.61 (&#8722;3.39 to 10.61)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Fourth</td><td valign="top" align="left" rowspan="1" colspan="1">13.93 (0.25 to 27.62)</td><td valign="top" align="left" rowspan="1" colspan="1">11.62 (2.43 to 20.8)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;1.67 (&#8722;5.27 to 1.93)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;2.45 (&#8722;16.28 to 11.39)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.92 (&#8722;18.98 to 17.14)</td><td valign="top" align="left" rowspan="1" colspan="1">4.70 (&#8722;3.84 to 13.24)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Fifth</td><td valign="top" align="left" rowspan="1" colspan="1">14.43 (2.61 to 26.26)</td><td valign="top" align="left" rowspan="1" colspan="1">11.43 (0.61 to 22.25)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;1.82 (&#8722;6.01 to 2.38)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;7.89 (&#8722;24.80 to 9.02)</td><td valign="top" align="left" rowspan="1" colspan="1">5.12 (&#8722;18.90 to 29.13)</td><td valign="top" align="left" rowspan="1" colspan="1">5.30 (&#8722;4.46 to 15.06)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: CME, continuing medical education; PDMP, prescription drug monitoring program.</p><fn id="aoi230025t3n1"><label>
<sup>a</sup>
</label><p>The point estimate is change in buprenorphine treatment months per 1000 county residents.</p></fn></table-wrap-foot></table-wrap></sec><sec id="H1-4-AOI230025"><title>Discussion</title><p>In this cross-sectional analysis of how multiple state laws were associated with buprenorphine dispensing outcomes, we found that requiring additional education of clinicians who prescribe buprenorphine beyond waiver requirements was associated with substantial increases in buprenorphine treatment per capita. To put this finding into context, in a county with 200&#8201;000 residents, by the fourth year after policy implementation, an increase of more than 10 additional patient-months per 1000 residents would result in an additional 333 individuals receiving buprenorphine treatment, assuming an average treatment episode of 6 months.</p><p>Multiple studies have found that clinician apprehensions about being sufficiently knowledgeable regarding buprenorphine treatment for OUD is a barrier to prescribing buprenorphine,<sup><xref rid="aoi230025r49" ref-type="bibr">49</xref>,<xref rid="aoi230025r50" ref-type="bibr">50</xref>,<xref rid="aoi230025r51" ref-type="bibr">51</xref>,<xref rid="aoi230025r52" ref-type="bibr">52</xref>,<xref rid="aoi230025r53" ref-type="bibr">53</xref></sup> and providing clinicians with additional education, training, or mentorship beyond the waiver requirement has been associated with increased buprenorphine treatment.<sup><xref rid="aoi230025r54" ref-type="bibr">54</xref>,<xref rid="aoi230025r55" ref-type="bibr">55</xref></sup> Given concern that requiring training just to obtain an X-waiver may have dissuaded clinicians from prescribing buprenorphine, it may seem counterintuitive that requiring additional training is associated with more buprenorphine prescribing. However, lack of confidence in treating patients and the clinical complexity of patients, issues that are commonly reported barriers to buprenorphine prescribing,<sup><xref rid="aoi230025r49" ref-type="bibr">49</xref>,<xref rid="aoi230025r51" ref-type="bibr">51</xref>,<xref rid="aoi230025r53" ref-type="bibr">53</xref>,<xref rid="aoi230025r56" ref-type="bibr">56</xref>,<xref rid="aoi230025r57" ref-type="bibr">57</xref>,<xref rid="aoi230025r58" ref-type="bibr">58</xref>,<xref rid="aoi230025r59" ref-type="bibr">59</xref></sup> may be addressed in ongoing training. Additional training may increase the buprenorphine-prescribing clinicians&#8217; confidence, enhancing their willingness to treat more patients or to keep patients in treatment longer. Our finding is consistent with studies showing that educational efforts, albeit not mandated by state policy, have been associated with increased buprenorphine prescribing.<sup><xref rid="aoi230025r54" ref-type="bibr">54</xref>,<xref rid="aoi230025r55" ref-type="bibr">55</xref>,<xref rid="aoi230025r60" ref-type="bibr">60</xref>,<xref rid="aoi230025r61" ref-type="bibr">61</xref></sup> Furthermore, recent research finding that federal relaxation of training requirements to obtain a waiver did not substantially increase the number of clinicians obtaining waivers suggests that the barrier presented by training may not be as great as many feared.<sup><xref rid="aoi230025r16" ref-type="bibr">16</xref>,<xref rid="aoi230025r62" ref-type="bibr">62</xref></sup></p><p>We also found a significant association between buprenorphine dispensing and laws requiring CME in substance misuse and addiction for physician relicensure. Concerns have been expressed about the adequacy of physician education regarding substance use disorders<sup><xref rid="aoi230025r63" ref-type="bibr">63</xref></sup> and primary care physician understanding of MOUD.<sup><xref rid="aoi230025r64" ref-type="bibr">64</xref></sup> Continuing medical education focused on substance use disorders and the treatment of such disorders may help to mitigate such knowledge gaps. Clinicians already confident or interested in substance use disorder treatment might self-select into voluntary CME courses. However, mandatory CME courses may alleviate concerns about addiction treatment or increase interest in addiction treatment among clinicians who would not otherwise choose such courses, thus potentially increasing the pool of buprenorphine prescribers. The Consolidated Appropriations Act of 2023 eliminated the requirement for waivers but requires the Substance Abuse and Mental Health Services Administration to establish training requirements related to substance misuse and addiction treatment for most clinicians obtaining a Drug Enforcement Administration license to prescribe controlled substances.<sup><xref rid="aoi230025r65" ref-type="bibr">65</xref></sup> Such training could help allay self-efficacy concerns among clinicians interested in prescribing buprenorphine for OUD, potentially increasing buprenorphine prescribing rates.</p><p>Even if CMEs do not increase the local pool of buprenorphine prescribers, they may increase awareness of buprenorphine treatment efficacy, leading clinicians to support patients&#8217; ongoing engagement in treatment and motivating nonprescribers encountering a patient with OUD to make an appropriate referral. Additional research is needed to better appreciate how required education is associated with buprenorphine treatment. However, our findings suggest that policies requiring additional education regarding substance misuse and substance use disorder treatment more generally may contribute to increased buprenorphine use.</p><p>Medicaid remains the predominant payer for OUD treatment.<sup><xref rid="aoi230025r66" ref-type="bibr">66</xref></sup> Studies have found an association between Medicaid expansion and Medicaid coverage of buprenorphine and increases in the number of buprenorphine-waivered prescribers, buprenorphine receipt among Medicaid-enrollees in the year after expansion, more dispensed buprenorphine prescriptions written by nurse practitioners and physician assistants, and fewer overdose deaths.<sup><xref rid="aoi230025r29" ref-type="bibr">29</xref>,<xref rid="aoi230025r30" ref-type="bibr">30</xref>,<xref rid="aoi230025r31" ref-type="bibr">31</xref>,<xref rid="aoi230025r67" ref-type="bibr">67</xref>,<xref rid="aoi230025r68" ref-type="bibr">68</xref></sup> In our analyses, we did not find Medicaid coverage for buprenorphine treatment or Medicaid expansion to be associated with buprenorphine treatment per capita. States that expanded Medicaid may differ substantially from those that did not with respect to other policies related to OUD treatment. We examined the outcomes of multiple relevant policies in a state simultaneously. Thus, our findings may be influenced by the fact that our analysis accounts for additional state policies likely to influence buprenorphine use. It is also possible that compared with Medicaid expansion states, states that did not expand Medicaid supported buprenorphine treatment with resources from short-term funding mechanisms, such as State Opioid Response grants and State Targeted Response grants established by the 21st Century Cures Act.<sup><xref rid="aoi230025r69" ref-type="bibr">69</xref>,<xref rid="aoi230025r70" ref-type="bibr">70</xref></sup> In addition, research has shown that increased buprenorphine treatment after Medicaid expansion was offset by decreases in treatment in other populations,<sup><xref rid="aoi230025r46" ref-type="bibr">46</xref></sup> a result consistent with other studies that found little effect of Medicaid expansion on overall rates of substance use disorder treatment in the general population.<sup><xref rid="aoi230025r71" ref-type="bibr">71</xref>,<xref rid="aoi230025r72" ref-type="bibr">72</xref></sup> Furthermore, multiple studies have found that many buprenorphine prescribers do not accept Medicaid.<sup><xref rid="aoi230025r73" ref-type="bibr">73</xref>,<xref rid="aoi230025r74" ref-type="bibr">74</xref></sup> Thus, our findings highlight the essential contribution of state policy efforts to expand access to buprenorphine treatment beyond Medicaid.</p><p>We also found no association with policies regulating pain management clinics or mandatory PDMP policies. Although pain specialists represent approximately 8% of buprenorphine prescribers<sup><xref rid="aoi230025r25" ref-type="bibr">25</xref></sup> and PDMPs could facilitate prescriber identification of individuals potentially misusing opioids, it seems likely that pain management clinics and PDMPs are more likely to influence opioid analgesic prescribing than to directly influence buprenorphine dispensing.</p><sec id="H2-5-AOI230025"><title>Limitations</title><p>Our findings must be considered within the context of study limitations. We restricted our analyses to buprenorphine formulations indicated for OUD treatment, but we cannot identify off-label prescriptions of those formulations. We do not know the clinical status of patients to whom buprenorphine was dispensed or the clinical setting in which prescriptions were written. We also lack information on patient race and ethnicity, factors associated with disparities in receiving buprenorphine.<sup><xref rid="aoi230025r75" ref-type="bibr">75</xref></sup> We do not know whether our results generalize to prescriptions dispensed from pharmacies not captured in the IQVIA data or to prescriptions written but not dispensed.</p><p>Prior to the elimination of the waiver, in recent years, multiple federal policies designed to increase the availability of buprenorphine had been implemented, including increasing patient limits for waivered prescribers,<sup><xref rid="aoi230025r76" ref-type="bibr">76</xref></sup> allowing clinicians other than physicians to obtain waivers or to manage the treatment of patients with OUD through collaborative relationships,<sup><xref rid="aoi230025r77" ref-type="bibr">77</xref>,<xref rid="aoi230025r78" ref-type="bibr">78</xref></sup> and permitting some clinicians to obtain a waiver without training.<sup><xref rid="aoi230025r15" ref-type="bibr">15</xref></sup> These efforts have substantially increased the number of buprenorphine-waivered clinicians, especially among nonphysician prescribers such as nurse practitioners and physician assistants.<sup><xref rid="aoi230025r76" ref-type="bibr">76</xref></sup> Buprenorphine dispensing could also be associated with other state policies, such as those addressing counseling requirements, prior authorization, clinician monitoring of patients, prescribing of buprenorphine by nonphysicians, state methadone policies, and state Section 1115 waivers of the Institutions for Medical Disease exclusion allowing use of Medicaid funds to treat substance use disorders in larger inpatient facilities.<sup><xref rid="aoi230025r79" ref-type="bibr">79</xref>,<xref rid="aoi230025r80" ref-type="bibr">80</xref>,<xref rid="aoi230025r81" ref-type="bibr">81</xref></sup></p><p>Unfortunately, we do not have the data required to examine the outcomes of such policies across all states and the entire study period, nor do we have sufficient current prescribing data to examine the outcomes associated with more recent policy changes. Our analytic approach does not allow us to examine US guidelines and nonpolicy efforts designed to increase buprenorphine prescribing, and we do not have systematic information about other efforts that may occur locally, regionally, or within health systems, such as the Veterans Administration.<sup><xref rid="aoi230025r20" ref-type="bibr">20</xref>,<xref rid="aoi230025r21" ref-type="bibr">21</xref>,<xref rid="aoi230025r82" ref-type="bibr">82</xref></sup> Our data also do not allow us to examine the outcomes of policies implemented during the COVID-19 pandemic that might be associated with dispensing of buprenorphine to treat OUD.</p></sec></sec><sec id="H1-5-AOI230025"><title>Conclusions</title><p>The findings from this cross-sectional study make an important contribution to the literature. Improving access to buprenorphine is essential to treating more patients with OUD effectively and decreasing overdoses and other OUD-related harms. Our study points to required education in substance misuse and substance use disorders as an actionable proposal for increasing buprenorphine use and ultimately serving more patients. This finding is important because the proposal is feasible to implement: CME and other requirements can be directly modified by state medical boards, are a relatively low burden for clinicians to complete, and can be targeted to groups of nonprescribing clinicians who serve patients who might benefit from buprenorphine. Thus, this model can be replicated in states currently without similar CME requirements. Continuing medical education is also a potential target for federal action, and state policies that would require controlled substance prescribers to have some basic training in the treatment of substance use disorders are in some ways similar to recently enacted federal legislation.<sup><xref rid="aoi230025r23" ref-type="bibr">23</xref></sup></p><p>No single policy lever can boost buprenorphine treatment to its optimal scale. However, achievable and meaningful changes in access may be achieved through greater attention to professional education and clinician knowledge. Moving forward, additional high-quality longitudinal policy data sets are needed to facilitate evaluation of policies intended to increase buprenorphine prescribing.</p></sec></body><back><ref-list id="REF-AOI230025"><title>References</title><ref id="aoi230025r1"><label>1</label><mixed-citation publication-type="webpage"><source>U.S. Overdose Deaths in 2021 increased half as much as in 2020&#8212;but are still up 15%</source>. <person-group><collab>Centers for Disease Control and Prevention National Center for Health Statistics</collab></person-group>; 2022. Accessed July 12, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/202205.htm" ext-link-type="uri">https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/202205.htm</ext-link></mixed-citation></ref><ref id="aoi230025r2"><label>2</label><mixed-citation publication-type="book"><person-group><collab>Substance Abuse and Mental Health Services Administration</collab></person-group>. <source>Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health</source>. HHS publication No. PEP20-07-01-001, NSDUH Series H-55. <publisher-name>Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration</publisher-name>; <year>2020</year>.</mixed-citation></ref><ref id="aoi230025r3"><label>3</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Keyes</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Rutherford</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hamilton</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? using multiplier approaches to estimate prevalence for an unknown population size</article-title>. <source>Drug Alcohol Depend Rep</source>. <year>2022</year>;<volume>3</volume>:<fpage>3</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.dadr.2022.100052</pub-id><pub-id pub-id-type="pmid">35783994</pub-id><pub-id pub-id-type="pmcid">PMC9248998</pub-id></mixed-citation></ref><ref id="aoi230025r4"><label>4</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Mauro</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Gutkind</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Annunziato</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Samples</surname><given-names>H</given-names></string-name></person-group>. <article-title>Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019</article-title>. <source>JAMA Netw Open</source>. <year>2022</year>;<volume>5</volume>(<issue>3</issue>):<elocation-id>e223821</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.3821</pub-id><pub-id pub-id-type="pmid">35319762</pub-id><pub-id pub-id-type="pmcid">PMC8943638</pub-id></mixed-citation></ref><ref id="aoi230025r5"><label>5</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Mattick</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Breen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kimber</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Davoli</surname><given-names>M</given-names></string-name></person-group>. <article-title>Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2014</year>;(<issue>2</issue>):<elocation-id>CD002207</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/14651858.CD002207.pub4</pub-id><pub-id pub-id-type="pmid">24500948</pub-id><pub-id pub-id-type="pmcid">PMC10617756</pub-id></mixed-citation></ref><ref id="aoi230025r6"><label>6</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Ponizovsky</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Margolis</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Heled</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Rosca</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Radomislensky</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Grinshpoon</surname><given-names>A</given-names></string-name></person-group>. <article-title>Improved quality of life, clinical, and psychosocial outcomes among heroin-dependent patients on ambulatory buprenorphine maintenance</article-title>. <source>Subst Use Misuse</source>. <year>2010</year>;<volume>45</volume>(<issue>1-2</issue>):<fpage>288</fpage>-<lpage>313</lpage>. doi:<pub-id pub-id-type="doi">10.3109/10826080902873010</pub-id><pub-id pub-id-type="pmid">20025454</pub-id></mixed-citation></ref><ref id="aoi230025r7"><label>7</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Giacomuzzi</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Riemer</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ertl</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment</article-title>. <source>Addiction</source>. <year>2003</year>;<volume>98</volume>(<issue>5</issue>):<fpage>693</fpage>-<lpage>702</lpage>. doi:<pub-id pub-id-type="doi">10.1046/j.1360-0443.2003.00352.x</pub-id><pub-id pub-id-type="pmid">12751987</pub-id></mixed-citation></ref><ref id="aoi230025r8"><label>8</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Larochelle</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Bernson</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Land</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study</article-title>. <source>Ann Intern Med</source>. <year>2018</year>;<volume>169</volume>(<issue>3</issue>):<fpage>137</fpage>-<lpage>145</lpage>. doi:<pub-id pub-id-type="doi">10.7326/M17-3107</pub-id><pub-id pub-id-type="pmid">29913516</pub-id><pub-id pub-id-type="pmcid">PMC6387681</pub-id></mixed-citation></ref><ref id="aoi230025r9"><label>9</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Golan</surname><given-names>OK</given-names></string-name>, <string-name name-style="western"><surname>Totaram</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Perry</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>Systematic review and meta-analysis of changes in quality of life following initiation of buprenorphine for opioid use disorder</article-title>. <source>Drug Alcohol Depend</source>. <year>2022</year>;<volume>235</volume>:<elocation-id>109445</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2022.109445</pub-id><pub-id pub-id-type="pmid">35430522</pub-id></mixed-citation></ref><ref id="aoi230025r10"><label>10</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>McBain</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Dick</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sorbero</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stein</surname><given-names>BD</given-names></string-name></person-group>. <article-title>Growth and distribution of buprenorphine-waivered providers in the United States, 2007-2017</article-title>. <source>Ann Intern Med</source>. <year>2020</year>;<volume>172</volume>(<issue>7</issue>):<fpage>504</fpage>-<lpage>506</lpage>. doi:<pub-id pub-id-type="doi">10.7326/M19-2403</pub-id><pub-id pub-id-type="pmid">31905379</pub-id><pub-id pub-id-type="pmcid">PMC7217729</pub-id></mixed-citation></ref><ref id="aoi230025r11"><label>11</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Dick</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Pacula</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></string-name>, <etal/></person-group>. <article-title>Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002-11</article-title>. <source>Health Aff (Millwood)</source>. <year>2015</year>;<volume>34</volume>(<issue>6</issue>):<fpage>1028</fpage>-<lpage>1034</lpage>. doi:<pub-id pub-id-type="doi">10.1377/hlthaff.2014.1205</pub-id><pub-id pub-id-type="pmid">26056209</pub-id><pub-id pub-id-type="pmcid">PMC4743254</pub-id></mixed-citation></ref><ref id="aoi230025r12"><label>12</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Stein</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Dick</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Sorbero</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees</article-title>. <source>Subst Abus</source>. <year>2018</year>;<volume>39</volume>(<issue>4</issue>):<fpage>419</fpage>-<lpage>425</lpage>. doi:<pub-id pub-id-type="doi">10.1080/08897077.2018.1449166</pub-id><pub-id pub-id-type="pmid">29932847</pub-id><pub-id pub-id-type="pmcid">PMC6309581</pub-id></mixed-citation></ref><ref id="aoi230025r13"><label>13</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Chen</surname><given-names>AY</given-names></string-name>, <string-name name-style="western"><surname>Powell</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Stein</surname><given-names>BD</given-names></string-name></person-group>. <article-title>Changes in buprenorphine and methadone supplies in the US during the COVID-19 pandemic</article-title>. <source>JAMA Netw Open</source>. <year>2022</year>;<volume>5</volume>(<issue>7</issue>):<elocation-id>e2223708</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.23708</pub-id><pub-id pub-id-type="pmid">35881394</pub-id><pub-id pub-id-type="pmcid">PMC9327579</pub-id></mixed-citation></ref><ref id="aoi230025r14"><label>14</label><mixed-citation publication-type="book"><person-group><collab>Substance Abuse and Mental Health Services Administration</collab></person-group>. <source>Key Substance Use and Mental Health Indicators in the United States: Results from the 2020 National Survey on Drug Use and Health</source>. HHS Publication No. PEP21-07-01-003, NSDUH Series H-56. <publisher-name>Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration</publisher-name>; <year>2021</year>.</mixed-citation></ref><ref id="aoi230025r15"><label>15</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Saloner</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Andraka Christou</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Stein</surname><given-names>BD</given-names></string-name></person-group>. <article-title>It will end in tiers: a strategy to include &#8220;dabblers&#8221; in the buprenorphine workforce after the X-waiver</article-title>. <source>Subst Abus</source>. <year>2021</year>;<volume>42</volume>(<issue>2</issue>):<fpage>153</fpage>-<lpage>157</lpage>. doi:<pub-id pub-id-type="doi">10.1080/08897077.2021.1903659</pub-id><pub-id pub-id-type="pmid">33798034</pub-id><pub-id pub-id-type="pmcid">PMC8667660</pub-id></mixed-citation></ref><ref id="aoi230025r16"><label>16</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Davis</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Carr</surname><given-names>DH</given-names></string-name></person-group>. <article-title>Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States</article-title>. <source>Int J Drug Policy</source>. <year>2019</year>;<volume>73</volume>:<fpage>42</fpage>-<lpage>48</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugpo.2019.07.006</pub-id><pub-id pub-id-type="pmid">31336293</pub-id></mixed-citation></ref><ref id="aoi230025r17"><label>17</label><mixed-citation publication-type="other">Comprehensive Addiction and Recovery Act of 2016. 114th Cong (2016). Pub L No. 114&#8211;198, 130 Stat 695. https://www.congress.gov/bill/114th-congress/senate-bill/524/text</mixed-citation></ref><ref id="aoi230025r18"><label>18</label><mixed-citation publication-type="webpage">Practice guidelines for the administration of buprenorphine for treating opioid use disorder. <italic toggle="yes">Fed Regist</italic>. 2021;86(80):22439-22440. Accessed May 4, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.govinfo.gov/content/pkg/FR-2021-04-28/pdf/2021-08961.pdf" ext-link-type="uri">https://www.govinfo.gov/content/pkg/FR-2021-04-28/pdf/2021-08961.pdf</ext-link></mixed-citation></ref><ref id="aoi230025r19"><label>19</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Egan</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Casadonte</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gartenmann</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment</article-title>. <source>J Gen Intern Med</source>. <year>2010</year>;<volume>25</volume>(<issue>9</issue>):<fpage>936</fpage>-<lpage>941</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11606-010-1377-y</pub-id><pub-id pub-id-type="pmid">20458550</pub-id><pub-id pub-id-type="pmcid">PMC2917666</pub-id></mixed-citation></ref><ref id="aoi230025r20"><label>20</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Drexler</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hawkins</surname><given-names>EJ</given-names></string-name>, <etal/></person-group>. <article-title>Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities</article-title>. <source>Subst Abus</source>. <year>2020</year>;<volume>41</volume>(<issue>3</issue>):<fpage>275</fpage>-<lpage>282</lpage>. doi:<pub-id pub-id-type="doi">10.1080/08897077.2020.1787299</pub-id><pub-id pub-id-type="pmid">32697170</pub-id><pub-id pub-id-type="pmcid">PMC7849630</pub-id></mixed-citation></ref><ref id="aoi230025r21"><label>21</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hawkins</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Malte</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></string-name>, <etal/></person-group>. <article-title>Accessibility to medication for opioid use disorder after interventions to improve prescribing among nonaddiction clinics in the US Veterans Health Care System</article-title>. <source>JAMA Netw Open</source>. <year>2021</year>;<volume>4</volume>(<issue>12</issue>):<elocation-id>e2137238</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.37238</pub-id><pub-id pub-id-type="pmid">34870679</pub-id><pub-id pub-id-type="pmcid">PMC8649831</pub-id></mixed-citation></ref><ref id="aoi230025r22"><label>22</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Andraka-Christou</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Bouskill</surname><given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>Toward a typology of office-based buprenorphine treatment laws: themes from a review of state laws</article-title>. <source>J Addict Med</source>. <year>2022</year>;<volume>16</volume>(<issue>2</issue>):<fpage>192</fpage>-<lpage>207</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000000863</pub-id><pub-id pub-id-type="pmid">34014209</pub-id><pub-id pub-id-type="pmcid">PMC8599526</pub-id></mixed-citation></ref><ref id="aoi230025r23"><label>23</label><mixed-citation publication-type="other">Consolidated Appropriations Act, HR 2617. 117th Cong (2022). Pub L No. 117-328. Accessed April 17, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.congress.gov/bill/117th-congress/house-bill/2617" ext-link-type="uri">https://www.congress.gov/bill/117th-congress/house-bill/2617</ext-link></mixed-citation></ref><ref id="aoi230025r24"><label>24</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Cabreros</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Griffin</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Saloner</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Kerber</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Stein</surname><given-names>BD</given-names></string-name></person-group>. <article-title>Buprenorphine prescriber monthly patient caseloads: an examination of 6-year trajectories</article-title>. <source>Drug Alcohol Depend</source>. <year>2021</year>;<volume>228</volume>:<elocation-id>109089</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2021.109089</pub-id><pub-id pub-id-type="pmid">34600259</pub-id><pub-id pub-id-type="pmcid">PMC8595760</pub-id></mixed-citation></ref><ref id="aoi230025r25"><label>25</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Stein</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Saloner</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Schuler</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Gurvey</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sorbero</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></string-name></person-group>. <article-title>Concentration of patient care among buprenorphine-prescribing clinicians in the US</article-title>. <source>JAMA</source>. <year>2021</year>;<volume>325</volume>(<issue>21</issue>):<fpage>2206</fpage>-<lpage>2208</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2021.4469</pub-id><pub-id pub-id-type="pmid">34061152</pub-id><pub-id pub-id-type="pmcid">PMC8170540</pub-id></mixed-citation></ref><ref id="aoi230025r26"><label>26</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Stein</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Sorbero</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dick</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Pacula</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Burns</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></string-name></person-group>. <article-title>Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment</article-title>. <source>JAMA</source>. <year>2016</year>;<volume>316</volume>(<issue>11</issue>):<fpage>1211</fpage>-<lpage>1212</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2016.10542</pub-id><pub-id pub-id-type="pmid">27654608</pub-id><pub-id pub-id-type="pmcid">PMC5257276</pub-id></mixed-citation></ref><ref id="aoi230025r27"><label>27</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Duncan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Anderman</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Deseran</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Reynolds</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Stein</surname><given-names>BD</given-names></string-name></person-group>. <article-title>Monthly patient volumes of buprenorphine-waivered clinicians in the US</article-title>. <source>JAMA Netw Open</source>. <year>2020</year>;<volume>3</volume>(<issue>8</issue>):<elocation-id>e2014045</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.14045</pub-id><pub-id pub-id-type="pmid">32833015</pub-id><pub-id pub-id-type="pmcid">PMC7445589</pub-id></mixed-citation></ref><ref id="aoi230025r28"><label>28</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Thomas</surname><given-names>CP</given-names></string-name>, <string-name name-style="western"><surname>Doyle</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Kreiner</surname><given-names>PW</given-names></string-name>, <etal/></person-group>. <article-title>Prescribing patterns of buprenorphine waivered physicians</article-title>. <source>Drug Alcohol Depend</source>. <year>2017</year>;<volume>181</volume>:<fpage>213</fpage>-<lpage>218</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2017.10.002</pub-id><pub-id pub-id-type="pmid">29096292</pub-id></mixed-citation></ref><ref id="aoi230025r29"><label>29</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Stein</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Dick</surname><given-names>AW</given-names></string-name>, <etal/></person-group>. <article-title>Supply of buprenorphine waivered physicians: the influence of state policies</article-title>. <source>J Subst Abuse Treat</source>. <year>2015</year>;<volume>48</volume>(<issue>1</issue>):<fpage>104</fpage>-<lpage>111</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2014.07.010</pub-id><pub-id pub-id-type="pmid">25218919</pub-id><pub-id pub-id-type="pmcid">PMC4420477</pub-id></mixed-citation></ref><ref id="aoi230025r30"><label>30</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Wen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hockenberry</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Borders</surname><given-names>TF</given-names></string-name>, <string-name name-style="western"><surname>Druss</surname><given-names>BG</given-names></string-name></person-group>. <article-title>Impact of Medicaid expansion on Medicaid-covered utilization of buprenorphine for opioid use disorder treatment</article-title>. <source>Med Care</source>. <year>2017</year>;<volume>55</volume>(<issue>4</issue>):<fpage>336</fpage>-<lpage>341</lpage>. doi:<pub-id pub-id-type="doi">10.1097/MLR.0000000000000703</pub-id><pub-id pub-id-type="pmid">28296674</pub-id></mixed-citation></ref><ref id="aoi230025r31"><label>31</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Saloner</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Levin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>H-Y</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Alexander</surname><given-names>GC</given-names></string-name></person-group>. <article-title>Changes in buprenorphine-naloxone and opioid pain reliever prescriptions after the Affordable Care Act Medicaid expansion</article-title>. <source>JAMA Netw Open</source>. <year>2018</year>;<volume>1</volume>(<issue>4</issue>):<elocation-id>e181588</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2018.1588</pub-id><pub-id pub-id-type="pmid">30646116</pub-id><pub-id pub-id-type="pmcid">PMC6324520</pub-id></mixed-citation></ref><ref id="aoi230025r32"><label>32</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Lee</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Ahn</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Perry</surname><given-names>BL</given-names></string-name></person-group>. <article-title>Systematic evaluation of state policy interventions targeting the US opioid epidemic, 2007-2018</article-title>. <source>JAMA Netw Open</source>. <year>2021</year>;<volume>4</volume>(<issue>2</issue>):<elocation-id>e2036687</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.36687</pub-id><pub-id pub-id-type="pmid">33576816</pub-id><pub-id pub-id-type="pmcid">PMC7881356</pub-id></mixed-citation></ref><ref id="aoi230025r33"><label>33</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Schuler</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Griffin</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Cerd&#225;</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>McGinty</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Stuart</surname><given-names>EA</given-names></string-name></person-group>. <article-title>Methodological challenges and proposed solutions for evaluating opioid policy effectiveness</article-title>. <source>Health Serv Outcomes Res Methodol</source>. <year>2021</year>;<volume>21</volume>(<issue>1</issue>):<fpage>21</fpage>-<lpage>41</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10742-020-00228-2</pub-id><pub-id pub-id-type="pmid">33883971</pub-id><pub-id pub-id-type="pmcid">PMC8057700</pub-id></mixed-citation></ref><ref id="aoi230025r34"><label>34</label><mixed-citation publication-type="webpage">Real world data and insights. <person-group><collab>IQVIA</collab></person-group>. Accessed July 13, 2020. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.iqvia.com/solutions/real-world-evidence/real-world-data-and-insights" ext-link-type="uri">https://www.iqvia.com/solutions/real-world-evidence/real-world-data-and-insights</ext-link></mixed-citation></ref><ref id="aoi230025r35"><label>35</label><mixed-citation publication-type="webpage">Annual county and resident population estimates by selected age groups and sex: April 1, 2010 to July 1, 2019 (CC-EST2019-AGESEX). <person-group><collab>US Census Bureau</collab></person-group>; <year>2021</year>. Accessed January 12, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.census.gov/programs-surveys/acs/data.html" ext-link-type="uri">https://www.census.gov/programs-surveys/acs/data.html</ext-link></mixed-citation></ref><ref id="aoi230025r36"><label>36</label><mixed-citation publication-type="book"><person-group><collab>National Center for Health Statistics</collab></person-group>. <source>2013 NCHS Urban&#8211;Rural Classification Scheme for Counties</source>. <volume>Vol 2</volume>. <publisher-name>Centers for Disease Control and Prevention</publisher-name>; <year>2014</year>.</mixed-citation></ref><ref id="aoi230025r37"><label>37</label><mixed-citation publication-type="webpage">Drug overdose mortality by state. <person-group><collab>Centers for Disease Control Prevention</collab></person-group>; 2020. Accessed May 20, 2020. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/nchs/pressroom/sosmap/drug_poisoning_mortality/drug_poisoning.htm" ext-link-type="uri">https://www.cdc.gov/nchs/pressroom/sosmap/drug_poisoning_mortality/drug_poisoning.htm</ext-link></mixed-citation></ref><ref id="aoi230025r38"><label>38</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Schuler</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Dick</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Stein</surname><given-names>BD</given-names></string-name></person-group>. <article-title>Growing racial/ethnic disparities in buprenorphine distribution in the United States, 2007-2017</article-title>. <source>Drug Alcohol Depend</source>. <year>2021</year>;<volume>223</volume>:<elocation-id>108710</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2021.108710</pub-id><pub-id pub-id-type="pmid">33873027</pub-id><pub-id pub-id-type="pmcid">PMC8204632</pub-id></mixed-citation></ref><ref id="aoi230025r39"><label>39</label><mixed-citation publication-type="webpage">American Community Survey data. <person-group><collab>US Census Bureau</collab></person-group>. Accessed April 17, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.census.gov/programs-surveys/acs/data.html" ext-link-type="uri">https://www.census.gov/programs-surveys/acs/data.html</ext-link></mixed-citation></ref><ref id="aoi230025r40"><label>40</label><mixed-citation publication-type="webpage"><person-group><collab>OPTIC-Vetted Policy Data Sets</collab></person-group>. RAND Corporation; <year>2021</year>. Accessed March 21, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rand.org/health-care/centers/optic/resources/datasets.html" ext-link-type="uri">https://www.rand.org/health-care/centers/optic/resources/datasets.html</ext-link></mixed-citation></ref><ref id="aoi230025r41"><label>41</label><mixed-citation publication-type="webpage">PDAPS&#8212;Pain management clinic laws. Prescription Drug Abuse Policy System; <year>2018</year>. Accessed February 22, 2021. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pdaps.org/datasets/pain-management-clinic-laws" ext-link-type="uri">https://pdaps.org/datasets/pain-management-clinic-laws</ext-link></mixed-citation></ref><ref id="aoi230025r42"><label>42</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Burns</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Pacula</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Bauhoff</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Policies related to opioid agonist therapy for opioid use disorders: the evolution of state policies from 2004 to 2013</article-title>. <source>Subst Abus</source>. <year>2016</year>;<volume>37</volume>(<issue>1</issue>):<fpage>63</fpage>-<lpage>69</lpage>. doi:<pub-id pub-id-type="doi">10.1080/08897077.2015.1080208</pub-id><pub-id pub-id-type="pmid">26566761</pub-id><pub-id pub-id-type="pmcid">PMC4801690</pub-id></mixed-citation></ref><ref id="aoi230025r43"><label>43</label><mixed-citation publication-type="webpage">Status of state action on the Medicaid expansion decision. <person-group><collab>Kaiser Family Foundation</collab></person-group>; <year>2021</year>. Accessed February 19, 2021. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.kff.org/health-reform/state-indicator/state-activity-around-expanding-medicaid-under-the-affordable-care-act/?currentTimeframe=0&amp;sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D" ext-link-type="uri">https://www.kff.org/health-reform/state-indicator/state-activity-around-expanding-medicaid-under-the-affordable-care-act/?currentTimeframe=0&amp;sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D</ext-link></mixed-citation></ref><ref id="aoi230025r44"><label>44</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Davis</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Lieberman</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Hernandez-Delgado</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Suba</surname><given-names>C</given-names></string-name></person-group>. <article-title>Laws limiting the prescribing or dispensing of opioids for acute pain in the United States: a national systematic legal review</article-title>. <source>Drug Alcohol Depend</source>. <year>2019</year>;<volume>194</volume>:<fpage>166</fpage>-<lpage>172</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2018.09.022</pub-id><pub-id pub-id-type="pmid">30445274</pub-id></mixed-citation></ref><ref id="aoi230025r45"><label>45</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Donohue</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Jarlenski</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>JY</given-names></string-name>, <etal/>; <collab>Medicaid Outcomes Distributed Research Network (MODRN)</collab></person-group>. <article-title>Use of medications for treatment of opioid use disorder among US Medicaid enrollees in 11 states, 2014-2018</article-title>. <source>JAMA</source>. <year>2021</year>;<volume>326</volume>(<issue>2</issue>):<fpage>154</fpage>-<lpage>164</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2021.7374</pub-id><pub-id pub-id-type="pmid">34255008</pub-id><pub-id pub-id-type="pmcid">PMC8278273</pub-id></mixed-citation></ref><ref id="aoi230025r46"><label>46</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Olfson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>VS</given-names></string-name>, <string-name name-style="western"><surname>King</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mojtabai</surname><given-names>R</given-names></string-name></person-group>. <article-title>Changes in buprenorphine treatment after Medicaid expansion</article-title>. <source>Psychiatr Serv</source>. <year>2021</year>;<volume>72</volume>(<issue>6</issue>):<fpage>633</fpage>-<lpage>640</lpage>. doi:<pub-id pub-id-type="doi">10.1176/appi.ps.202000491</pub-id><pub-id pub-id-type="pmid">33730878</pub-id><pub-id pub-id-type="pmcid">PMC9097622</pub-id></mixed-citation></ref><ref id="aoi230025r47"><label>47</label><mixed-citation publication-type="preprint"><person-group><string-name name-style="western"><surname>Borusyak</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Jaravel</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Spiess</surname><given-names>J</given-names></string-name></person-group>. <article-title>Revisiting event study designs: robust and efficient estimation</article-title>. <source>arXiv</source>. Preprint posted online August 27, 2021. doi:<pub-id pub-id-type="doi">10.48550/arXiv.2108.12419</pub-id></mixed-citation></ref><ref id="aoi230025r48"><label>48</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Goodman-Bacon</surname><given-names>A</given-names></string-name></person-group>. <article-title>Difference-in-differences with variation in treatment timing</article-title>. <source>J Econom</source>. <year>2021</year>;<volume>225</volume>(<issue>2</issue>):<fpage>254</fpage>-<lpage>277</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jeconom.2021.03.014</pub-id></mixed-citation></ref><ref id="aoi230025r49"><label>49</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Winograd</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Coffey</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Woolfolk</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>To prescribe or not to prescribe? barriers and motivators for progressing along each stage of the buprenorphine training and prescribing path</article-title>. <source>J Behav Health Serv Res</source>. <year>2023</year>;<volume>50</volume>(<issue>2</issue>):<fpage>165</fpage>-<lpage>180</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11414-021-09783-z</pub-id><pub-id pub-id-type="pmid">35060002</pub-id></mixed-citation></ref><ref id="aoi230025r50"><label>50</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Foti</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Heyward</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tajanlangit</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Primary care physicians&#8217; preparedness to treat opioid use disorder in the United States: a cross-sectional survey</article-title>. <source>Drug Alcohol Depend</source>. <year>2021</year>;<volume>225</volume>:<elocation-id>108811</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2021.108811</pub-id><pub-id pub-id-type="pmid">34175786</pub-id><pub-id pub-id-type="pmcid">PMC10659122</pub-id></mixed-citation></ref><ref id="aoi230025r51"><label>51</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Mackey</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Veazie</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bourne</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Peterson</surname><given-names>K</given-names></string-name></person-group>. <article-title>Barriers and facilitators to the use of medications for opioid use disorder: a rapid review</article-title>. <source>J Gen Intern Med</source>. <year>2020</year>;<volume>35</volume>(<issue>suppl 3</issue>):<fpage>954</fpage>-<lpage>963</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11606-020-06257-4</pub-id><pub-id pub-id-type="pmid">33145687</pub-id><pub-id pub-id-type="pmcid">PMC7728943</pub-id></mixed-citation></ref><ref id="aoi230025r52"><label>52</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Jones</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>McCance-Katz</surname><given-names>EF</given-names></string-name></person-group>. <article-title>Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder</article-title>. <source>Addiction</source>. <year>2019</year>;<volume>114</volume>(<issue>3</issue>):<fpage>471</fpage>-<lpage>482</lpage>. doi:<pub-id pub-id-type="doi">10.1111/add.14436</pub-id><pub-id pub-id-type="pmid">30194876</pub-id></mixed-citation></ref><ref id="aoi230025r53"><label>53</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Andrilla</surname><given-names>CHA</given-names></string-name>, <string-name name-style="western"><surname>Coulthard</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Larson</surname><given-names>EH</given-names></string-name></person-group>. <article-title>Barriers rural physicians face prescribing buprenorphine for opioid use disorder</article-title>. <source>Ann Fam Med</source>. <year>2017</year>;<volume>15</volume>(<issue>4</issue>):<fpage>359</fpage>-<lpage>362</lpage>. doi:<pub-id pub-id-type="doi">10.1370/afm.2099</pub-id><pub-id pub-id-type="pmid">28694273</pub-id><pub-id pub-id-type="pmcid">PMC5505456</pub-id></mixed-citation></ref><ref id="aoi230025r54"><label>54</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Zittleman</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Curcija</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Nease</surname><given-names>DE</given-names><suffix>Jr</suffix></string-name>, <etal/></person-group>. <article-title>Increasing capacity for treatment of opioid use disorder in rural primary care practices</article-title>. <source>Ann Fam Med</source>. <year>2022</year>;<volume>20</volume>(<issue>1</issue>):<fpage>18</fpage>-<lpage>23</lpage>. doi:<pub-id pub-id-type="doi">10.1370/afm.2757</pub-id><pub-id pub-id-type="pmid">35074763</pub-id><pub-id pub-id-type="pmcid">PMC8786417</pub-id></mixed-citation></ref><ref id="aoi230025r55"><label>55</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Anderson</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Gadomski</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Project ECHO and primary care buprenorphine treatment for opioid use disorder: implementation and clinical outcomes</article-title>. <source>Subst Abus</source>. <year>2022</year>;<volume>43</volume>(<issue>1</issue>):<fpage>222</fpage>-<lpage>230</lpage>. doi:<pub-id pub-id-type="doi">10.1080/08897077.2021.1931633</pub-id><pub-id pub-id-type="pmid">34086529</pub-id></mixed-citation></ref><ref id="aoi230025r56"><label>56</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Lai</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Croghan</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Ebbert</surname><given-names>JO</given-names></string-name></person-group>. <article-title>Buprenorphine waiver attitudes among primary care providers</article-title>. <source>J Prim Care Community Health</source>. <year>2022</year>;<volume>13</volume>:<elocation-id>21501319221112272</elocation-id>. doi:<pub-id pub-id-type="doi">10.1177/21501319221112272</pub-id><pub-id pub-id-type="pmid">35822763</pub-id><pub-id pub-id-type="pmcid">PMC9284198</pub-id></mixed-citation></ref><ref id="aoi230025r57"><label>57</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Andraka-Christou</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Capone</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices</article-title>. <source>Int J Drug Policy</source>. <year>2018</year>;<volume>54</volume>:<fpage>9</fpage>-<lpage>17</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugpo.2017.11.021</pub-id><pub-id pub-id-type="pmid">29324253</pub-id></mixed-citation></ref><ref id="aoi230025r58"><label>58</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hutchinson</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Catlin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Andrilla</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Baldwin</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Rosenblatt</surname><given-names>RA</given-names></string-name></person-group>. <article-title>Barriers to primary care physicians prescribing buprenorphine</article-title>. <source>Ann Fam Med</source>. <year>2014</year>;<volume>12</volume>(<issue>2</issue>):<fpage>128</fpage>-<lpage>133</lpage>. doi:<pub-id pub-id-type="doi">10.1370/afm.1595</pub-id><pub-id pub-id-type="pmid">24615308</pub-id><pub-id pub-id-type="pmcid">PMC3948759</pub-id></mixed-citation></ref><ref id="aoi230025r59"><label>59</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Haffajee</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Bohnert</surname><given-names>ASB</given-names></string-name>, <string-name name-style="western"><surname>Lagisetty</surname><given-names>PA</given-names></string-name></person-group>. <article-title>Policy pathways to address provider workforce barriers to buprenorphine treatment</article-title>. <source>Am J Prev Med</source>. <year>2018</year>;<volume>54</volume>(<issue>6</issue>)(<supplement>suppl 3</supplement>):<fpage>S230</fpage>-<lpage>S242</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.amepre.2017.12.022</pub-id><pub-id pub-id-type="pmid">29779547</pub-id><pub-id pub-id-type="pmcid">PMC6330240</pub-id></mixed-citation></ref><ref id="aoi230025r60"><label>60</label><mixed-citation publication-type="webpage"><source>State of the response: state actions to address the pandemic report methodology</source>. <person-group><collab>National Safety Council</collab></person-group>. Accessed October 17, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nsc.org/getmedia/10cf1e25-92af-4caa-b5c1-b22114468cf1/state-response-report-methodology.pdf" ext-link-type="uri">https://www.nsc.org/getmedia/10cf1e25-92af-4caa-b5c1-b22114468cf1/state-response-report-methodology.pdf</ext-link></mixed-citation></ref><ref id="aoi230025r61"><label>61</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Molfenter</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>JS</given-names></string-name>, <etal/></person-group>. <article-title>Enhancing use of medications for opioid use disorder through external coaching</article-title>. <source>Psychiatr Serv</source>. <year>2023</year>;<volume>74</volume>(<issue>3</issue>):<fpage>265</fpage>-<lpage>271</lpage>. doi:<pub-id pub-id-type="doi">10.1176/appi.ps.202100675</pub-id><pub-id pub-id-type="pmid">36196533</pub-id><pub-id pub-id-type="pmcid">PMC10836327</pub-id></mixed-citation></ref><ref id="aoi230025r62"><label>62</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Spetz</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hailer</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gay</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Changes in US clinician waivers to prescribe buprenorphine management for opioid use disorder during the COVID-19 pandemic and after relaxation of training requirements</article-title>. <source>JAMA Netw Open</source>. <year>2022</year>;<volume>5</volume>(<issue>5</issue>):<elocation-id>e225996</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.5996</pub-id><pub-id pub-id-type="pmid">35552728</pub-id><pub-id pub-id-type="pmcid">PMC9099425</pub-id></mixed-citation></ref><ref id="aoi230025r63"><label>63</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Wood</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Samet</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Volkow</surname><given-names>ND</given-names></string-name></person-group>. <article-title>Physician education in addiction medicine</article-title>. <source>JAMA</source>. <year>2013</year>;<volume>310</volume>(<issue>16</issue>):<fpage>1673</fpage>-<lpage>1674</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2013.280377</pub-id><pub-id pub-id-type="pmid">24150462</pub-id><pub-id pub-id-type="pmcid">PMC4827345</pub-id></mixed-citation></ref><ref id="aoi230025r64"><label>64</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>McGinty</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Stone</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Kennedy-Hendricks</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bachhuber</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Barry</surname><given-names>CL</given-names></string-name></person-group>. <article-title>Medication for opioid use disorder: a national survey of primary care physicians</article-title>. <source>Ann Intern Med</source>. <year>2020</year>;<volume>173</volume>(<issue>2</issue>):<fpage>160</fpage>-<lpage>162</lpage>. doi:<pub-id pub-id-type="doi">10.7326/M19-3975</pub-id><pub-id pub-id-type="pmid">32311740</pub-id><pub-id pub-id-type="pmcid">PMC8171002</pub-id></mixed-citation></ref><ref id="aoi230025r65"><label>65</label><mixed-citation publication-type="webpage"><person-group><string-name name-style="western"><surname>Davis</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Lieberman</surname><given-names>A</given-names></string-name></person-group>. <source>Harm reduction and overdose prevention fact sheet: removal of the &#8220;X-waiver&#8221; requirement</source>. <person-group><collab>Network for Public Health Law</collab></person-group>; <year>2023</year>. Accessed March 21, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.networkforphl.org/wp-content/uploads/2023/02/Removal-of-the-X-Waiver-Requirement-Fact-Sheet.pdf" ext-link-type="uri">https://www.networkforphl.org/wp-content/uploads/2023/02/Removal-of-the-X-Waiver-Requirement-Fact-Sheet.pdf</ext-link></mixed-citation></ref><ref id="aoi230025r66"><label>66</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Feder</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Mojtabai</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Krawczyk</surname><given-names>N</given-names></string-name>, <etal/></person-group>. <article-title>Trends in insurance coverage and treatment among persons with opioid use disorders following the Affordable Care Act</article-title>. <source>Drug Alcohol Depend</source>. <year>2017</year>;<volume>179</volume>:<fpage>271</fpage>-<lpage>274</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2017.07.015</pub-id><pub-id pub-id-type="pmid">28823834</pub-id><pub-id pub-id-type="pmcid">PMC5612778</pub-id></mixed-citation></ref><ref id="aoi230025r67"><label>67</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Harrison</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Kerber</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Andraka-Christou</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sorbero</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stein</surname><given-names>BD</given-names></string-name></person-group>. <article-title>State policies and buprenorphine prescribing by nurse practitioners and physician assistants</article-title>. <source>Med Care Res Rev</source>. <year>2022</year>;<volume>79</volume>(<issue>6</issue>):<fpage>789</fpage>-<lpage>797</lpage>. doi:<pub-id pub-id-type="doi">10.1177/10775587221086489</pub-id><pub-id pub-id-type="pmid">35435071</pub-id><pub-id pub-id-type="pmcid">PMC10088360</pub-id></mixed-citation></ref><ref id="aoi230025r68"><label>68</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Kravitz-Wirtz</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Ponicki</surname><given-names>WR</given-names></string-name>, <etal/></person-group>. <article-title>Association of Medicaid expansion with opioid overdose mortality in the United States</article-title>. <source>JAMA Netw Open</source>. <year>2020</year>;<volume>3</volume>(<issue>1</issue>):<elocation-id>e1919066</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.19066</pub-id><pub-id pub-id-type="pmid">31922561</pub-id><pub-id pub-id-type="pmcid">PMC6991255</pub-id></mixed-citation></ref><ref id="aoi230025r69"><label>69</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Katcher</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Ruhm</surname><given-names>CJ</given-names></string-name></person-group>. <article-title>Federal opioid grant funding favors least populous states, not states with greatest need</article-title>. <source>Health Aff (Millwood)</source>. <year>2021</year>;<volume>40</volume>(<issue>5</issue>):<fpage>829</fpage>-<lpage>836</lpage>. doi:<pub-id pub-id-type="doi">10.1377/hlthaff.2020.01656</pub-id><pub-id pub-id-type="pmid">33939505</pub-id></mixed-citation></ref><ref id="aoi230025r70"><label>70</label><mixed-citation publication-type="webpage"><person-group><string-name name-style="western"><surname>Murrin</surname><given-names>S</given-names></string-name></person-group>. <source>States&#8217; use of grant funding for a targeted response to the opioid crisis</source>. <person-group><collab>US Dept of Health &amp; Human Services Office of Inspector General</collab></person-group>; <year>2020</year>. Accessed July 27, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://oig.hhs.gov/oei/reports/oei-BL-18-00460.pdf" ext-link-type="uri">https://oig.hhs.gov/oei/reports/oei-BL-18-00460.pdf</ext-link></mixed-citation></ref><ref id="aoi230025r71"><label>71</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Andrews</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Pollack</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Abraham</surname><given-names>AJ</given-names></string-name>, <etal/></person-group>. <article-title>Medicaid coverage in substance use disorder treatment after the affordable care act</article-title>. <source>J Subst Abuse Treat</source>. <year>2019</year>;<volume>102</volume>:<fpage>1</fpage>-<lpage>7</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2019.04.002</pub-id><pub-id pub-id-type="pmid">31202283</pub-id><pub-id pub-id-type="pmcid">PMC6578872</pub-id></mixed-citation></ref><ref id="aoi230025r72"><label>72</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Saloner</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Bandara</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>McGinty</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Barry</surname><given-names>CL</given-names></string-name></person-group>. <article-title>Trends in the use of treatment for substance use disorders, 2010-19</article-title>. <source>Health Aff (Millwood)</source>. <year>2022</year>;<volume>41</volume>(<issue>5</issue>):<fpage>696</fpage>-<lpage>702</lpage>. doi:<pub-id pub-id-type="doi">10.1377/hlthaff.2021.01767</pub-id><pub-id pub-id-type="pmid">35500189</pub-id><pub-id pub-id-type="pmcid">PMC10161241</pub-id></mixed-citation></ref><ref id="aoi230025r73"><label>73</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Patrick</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Richards</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Dupont</surname><given-names>WD</given-names></string-name>, <etal/></person-group>. <article-title>Association of pregnancy and insurance status with treatment access for opioid use disorder</article-title>. <source>JAMA Netw Open</source>. <year>2020</year>;<volume>3</volume>(<issue>8</issue>):<elocation-id>e2013456</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.13456</pub-id><pub-id pub-id-type="pmid">32797175</pub-id><pub-id pub-id-type="pmcid">PMC7428808</pub-id></mixed-citation></ref><ref id="aoi230025r74"><label>74</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Beetham</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Saloner</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wakeman</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Gaye</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Barnett</surname><given-names>ML</given-names></string-name></person-group>. <article-title>Access to office-based buprenorphine treatment in areas with high rates of opioid-related mortality: an audit study</article-title>. <source>Ann Intern Med</source>. <year>2019</year>;<volume>171</volume>(<issue>1</issue>):<fpage>1</fpage>-<lpage>9</lpage>. doi:<pub-id pub-id-type="doi">10.7326/M18-3457</pub-id><pub-id pub-id-type="pmid">31158849</pub-id><pub-id pub-id-type="pmcid">PMC7164610</pub-id></mixed-citation></ref><ref id="aoi230025r75"><label>75</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Lagisetty</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Ross</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bohnert</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Clay</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Maust</surname><given-names>DT</given-names></string-name></person-group>. <article-title>Buprenorphine treatment divide by race/ethnicity and payment</article-title>. <source>JAMA Psychiatry</source>. <year>2019</year>;<volume>76</volume>(<issue>9</issue>):<fpage>979</fpage>-<lpage>981</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2019.0876</pub-id><pub-id pub-id-type="pmid">31066881</pub-id><pub-id pub-id-type="pmcid">PMC6506898</pub-id></mixed-citation></ref><ref id="aoi230025r76"><label>76</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Ghertner</surname><given-names>R</given-names></string-name></person-group>. <article-title>U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018</article-title>. <source>Drug Alcohol Depend</source>. <year>2019</year>;<volume>204</volume>:<elocation-id>107527</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2019.06.029</pub-id><pub-id pub-id-type="pmid">31525570</pub-id></mixed-citation></ref><ref id="aoi230025r77"><label>77</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Cochran</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bruneau</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cox</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></string-name></person-group>. <article-title>Medication treatment for opioid use disorder and community pharmacy: expanding care during a national epidemic and global pandemic</article-title>. <source>Subst Abus</source>. <year>2020</year>;<volume>41</volume>(<issue>3</issue>):<fpage>269</fpage>-<lpage>274</lpage>. doi:<pub-id pub-id-type="doi">10.1080/08897077.2020.1787300</pub-id><pub-id pub-id-type="pmid">32697171</pub-id><pub-id pub-id-type="pmcid">PMC7444094</pub-id></mixed-citation></ref><ref id="aoi230025r78"><label>78</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Barnett</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Frank</surname><given-names>RG</given-names></string-name></person-group>. <article-title>In rural areas, buprenorphine waiver adoption since 2017 driven by nurse practitioners and physician assistants</article-title>. <source>Health Aff (Millwood)</source>. <year>2019</year>;<volume>38</volume>(<issue>12</issue>):<fpage>2048</fpage>-<lpage>2056</lpage>. doi:<pub-id pub-id-type="doi">10.1377/hlthaff.2019.00859</pub-id><pub-id pub-id-type="pmid">31794302</pub-id><pub-id pub-id-type="pmcid">PMC6938159</pub-id></mixed-citation></ref><ref id="aoi230025r79"><label>79</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Abraham</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Andrews</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Harris</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Westlake</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Grogan</surname><given-names>CM</given-names></string-name></person-group>. <article-title>Coverage and prior authorization policies for medications for opioid use disorder in Medicaid managed care</article-title>. <source>JAMA Health Forum</source>. <year>2022</year>;<volume>3</volume>(<issue>11</issue>):<elocation-id>e224001</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamahealthforum.2022.4001</pub-id><pub-id pub-id-type="pmid">36331441</pub-id><pub-id pub-id-type="pmcid">PMC10157383</pub-id></mixed-citation></ref><ref id="aoi230025r80"><label>80</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Andraka-Christou</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Spetz</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Beyond state scope of practice laws for advanced practitioners: additional supervision requirements for buprenorphine prescribing</article-title>. <source>J Subst Abuse Treat</source>. <year>2022</year>;<volume>138</volume>:<elocation-id>108715</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2021.108715</pub-id><pub-id pub-id-type="pmid">35067400</pub-id><pub-id pub-id-type="pmcid">PMC9167216</pub-id></mixed-citation></ref><ref id="aoi230025r81"><label>81</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Andraka-Christou</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Saloner</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></string-name>, <etal/></person-group>. <article-title>Laws for expanding access to medications for opioid use disorder: a legal analysis of 16 states &amp; Washington D.C</article-title>. <source>Am J Drug Alcohol Abuse</source>. <year>2022</year>;<volume>48</volume>(<issue>4</issue>):<fpage>492</fpage>-<lpage>503</lpage>. doi:<pub-id pub-id-type="doi">10.1080/00952990.2022.2082301</pub-id><pub-id pub-id-type="pmid">35772010</pub-id><pub-id pub-id-type="pmcid">PMC10336699</pub-id></mixed-citation></ref><ref id="aoi230025r82"><label>82</label><mixed-citation publication-type="other">Physicians to get waiver and training to prescribe buprenorphine. <person-group><collab>City of Philadelphia</collab></person-group>; <year>2020</year>. Accessed January 7, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.phila.gov/2020-02-25-physicians-to-get-waiver-and-training-to-prescribe-buprenorphine" ext-link-type="uri">https://www.phila.gov/2020-02-25-physicians-to-get-waiver-and-training-to-prescribe-buprenorphine</ext-link></mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-AOI230025-1"><supplementary-material id="note-AOI230025-1-s" position="float" content-type="local-data" orientation="portrait"><label>Supplement 1.</label><caption><p><bold>eMethods.</bold> Detailed Description of Methods</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamahealthforum-e231102-s001.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 2.</label><caption><p>
Data Sharing Statement
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamahealthforum-e231102-s002.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></notes></back></article></pmc-articleset>